Bio-Techne (TECH) Form 144: Insider Sale of 17,040 Shares ($960K)

Form 144 filed for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 common shares via Morgan Stanley Smith Barney LLC on 08/25/2025.

Rhea-AI Filing Summary

Form 144 filed for Bio-Techne Corp. (TECH) reports a proposed sale of 17,040 common shares via Morgan Stanley Smith Barney LLC on 08/25/2025. The filing shows an aggregate market value of $960,388.03 and notes 155,549,587 shares outstanding, indicating the sale represents a very small fraction of the company’s outstanding stock. The shares were acquired and paid for on 08/25/2025 through a stock option exercise paid in cash. The filer certifies they are not aware of undisclosed material adverse information. No other sales in the past three months are reported.

Insights

Securities Analyst

TL;DR: Insider exercised options and intends to sell a small block (0.011%) of outstanding shares; transaction appears routine and non-material.

The filing discloses a single proposed sale of 17,040 shares valued at about $960k executed through Morgan Stanley. Compared with 155.55 million shares outstanding, this is immaterial to capitalization and unlikely to affect liquidity or share price materially. The immediate acquisition and sale on the same date via option exercise suggests routine insider liquidity rather than a change in company fundamentals. No prior three‑month sales were reported, reducing concerns about accelerated insider disposition.

Corporate Governance Expert

TL;DR: Transaction follows Rule 144 disclosure requirements; no governance red flags evident from this filing alone.

The filer affirms absence of undisclosed material adverse information and the filing lists broker, acquisition method (stock option exercise), and payment in cash. These elements meet standard disclosure expectations under Rule 144. Because the sale is small relative to outstanding shares and no clustered insider sales are reported, the filing does not by itself indicate governance or compliance issues. Additional context (e.g., officer identity, any trading plan) is not provided in this document.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bio-Techne (TECH) disclose in this Form 144?

The filing discloses a proposed sale of 17,040 common shares valued at $960,388.03 to be executed on 08/25/2025 via Morgan Stanley Smith Barney LLC.

How were the shares acquired that are being sold under Form 144?

The shares were acquired on 08/25/2025 through a stock option exercise, and payment was made in cash on the same date.

What portion of Bio-Techne’s outstanding stock does this proposed sale represent?

The filing reports 155,549,587 shares outstanding; the 17,040 shares represent a very small fraction (approximately 0.011%) of outstanding shares.

Were any other securities sold by the same person in the past three months?

The document states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale?

The brokerage listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/25/2025 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001492695
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BIO-TECHNE CORPORATION
SEC File Number	000-17272
Address of Issuer	614 McKinley Place N.E. Minneapolis MINNESOTA 55413
Phone	612-379-8854
Name of Person for Whose Account the Securities are To Be Sold	ROELAND NUSSE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	17040	960388.03	155549587	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2025	Stock Option Exercise	Issuer			17040	08/25/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/25/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Roeland Nusse
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)